UBC Faculty Research and Publications

Competing risks of mortality by PAM50 intrinsic subtype of British Columbia tamoxifen-treated cohort of post-menopausal breast cancer patients Chapman, Judith-Anne W.; Liu, Shuzhen; Leung, Samuel; Nielsen, Torsten


Background: PAM50 intrinsic subtypes have been shown to impact breast cancer prognosis. Methods: A British Columbia cohort of 718 post-menopausal women treated with tamoxifen, without chemotherapy, had tumours intrinsic-subtyped (Luminal A;Luminal B;Basal;HER2) and centrally-reviewed by immunohistochemical (IHC) for estrogen and progesterone receptor (ER and PgR). We tested whether intrinsic subtype and other patient and tumour characteristics were associated with type of death. Results: At median 11.7 years follow-up, 429 of 718 (60%) women died: 30% of deaths were breast cancer-specific (BrCa); 30%, other type (OT). In 425 women 70, 27% died of BrCa and 45% of OT. Intrinsic subtype was associated with BrCa (p=0.001); and older age, with OT (p

Item Citations and Data


Attribution-NonCommercial-NoDerivatives 4.0 International

Usage Statistics